Angong Niuhuang pills with different bovine bezoar sources for acute ischemic stroke

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a single-center, open-label, controlled trial enrolling 100 participants into two active formulation groups (40 each) and a 20-person control group with 84 days of follow-up. Participants are adults aged 18–80 with confirmed acute ischemic stroke within 48 hours and NIHSS scores of 4–20, and must meet specified traditional Chinese medicine diagnostic criteria. The primary aim is to compare the efficacy and safety of Angong Niuhuang pills from two manufacturers on clinical functional outcomes and prognosis, while secondary analyses will measure changes in gut microbiota, peripheral immune function, and inflammatory markers. Clinical data, imaging, and biospecimens will be collected prospectively to link clinical effects with biological measures.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Participants or their legal guardians must be capable of understanding the study's purpose and risks and provide informed consent.
* Eligible subjects are aged 18-80 years (inclusive) at the time of consent, regardless of gender.
* All individuals of childbearing potential and male participants must use effective contraception during the study and for at least 6 months after the last dose of the investigational treatment. Additionally, participants must refrain from donating sperm or eggs during the study and for at least 6 months post-treatment.
* Inclusion criteria included: confirmed diagnosis of acute ischemic stroke (AIS) with symptom onset ≤48 hours, NIHSS score of 4-20 (with NIHSS category 1a \[level of consciousness\] ≥1), and exclusion of intracranial hemorrhage confirmed by imaging (CT or MRI).
* Participants must meet traditional Chinese medicine (TCM) diagnostic criteria for stroke (per the Diagnostic and Efficacy Evaluation Standards for Stroke in TCM issued by the State Administration of Traditional Chinese Medicine), including:Primary symptoms: Hemiplegia, altered consciousness, slurred speech or aphasia, sensory disturbance, facial deviation.Secondary symptoms: Headache, dizziness, pupillary abnormalities, dysphagia, gaze deviation, ataxia.Diagnosis requires ≥2 primary symptoms or 1 primary symptom plus ≥2 secondary symptoms. Written informed consent must be obtained.

Exclusion Criteria:

* Hemorrhagic or mixed stroke.
* Severe cardiac, hepatic, or renal dysfunction or malignancy.
* Prior stroke resulting in a baseline modified Rankin Scale (mRS) score \>3.
* Use of medications judged by the investigator to significantly affect gut microbiota or immune function (e.g., antibiotics, immunosuppressants) during the window period (3 days before baseline to 14±3 days post-treatment).
* Allergy to the investigational product or its components.
* Prior participation in this study.
* Blood donation (≥1 unit) within 90 days, plasma donation within 1 week, or platelet donation within 6 weeks before screening.
* Pregnancy, lactation, or plans for pregnancy/breastfeeding during the study or within 30 days post-treatment.
* Concurrent or recent (within 90 days) participation in other clinical trials.
* Clinically significant suicidal ideation or behavior within the past 12 months per Columbia-Suicide Severity Rating Scale (C-SSRS).
* Inability or unwillingness to comply with protocol requirements.
* Significant hearing/visual impairment, language barriers, claustrophobia, or other conditions interfering with neuropsychological assessments or MRI.
* Any other unspecified reasons deemed by the investigator to disqualify participation.

Where it's running

• Tongji Hospital
  Wuhan, Hubei, China Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Short-Term outside-in nerve stimulation for acute ischemic stroke

  This trial tests whether a 5-day external trigeminal nerve stimulation given after stroke can help more patients recover better than a sham treatment.

  Recruiting Xidian University · Xi'an · NCT07911605

• Sevoflurane vs. Propofol for anesthesia in stroke patients undergoing clot-removal

  This study tests whether sevoflurane or propofol used for anesthesia during endovascular treatment of an acute ischemic stroke affects the final brain damage and recovery.

  Recruiting Phase 3 Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · Barcelona · NCT07902791

• Safety of adding NRICM301 to standard care for adults with acute ischemic stroke

  This study tests whether adding NRICM301, a traditional Chinese medicine formula, to usual care is safe for adults with acute ischemic stroke.

  Recruiting En Chu Kong Hospital · New Taipei City · NCT07900503

• Intracranial Recanalization with LT3001 in Acute Ischemic Stroke

  This phase II study tests whether LT3001 given to adults with acute ischemic stroke can help reopen blocked brain arteries.

  Recruiting Phase 2 Lumosa Therapeutics Co., Ltd. · Taichung · NCT07890298

• Mobilisation After Endovascular Stroke Treatment

  This study checks whether moving around 12 hours after endovascular stroke treatment is as safe as moving around 24 hours for people with an acute ischemic stroke.

  Recruiting at 2 sites Karolinska Institutet · Tampere and 1 other locations · NCT07860333

• Endovascular therapy plus standard care vs standard care alone for distal and medium vessel strokes

  In people with acute ischemic stroke due to distal or medium vessel blockages, this study tests whether adding endovascular treatment to the usual medical care helps improve outcomes compared with medical care alone.

  Recruiting Hospital Universitari Vall d'Hebron Research Institute · Barcelona, Barcelona · NCT07843797

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.